Back to Search
Start Over
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
- Source :
- Leukemia. 23:1329-1336
- Publication Year :
- 2009
- Publisher :
- Springer Science and Business Media LLC, 2009.
-
Abstract
- We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with rituximab, analyzing the quantitative alteration of target molecules, that is, CD20, CD22, CD55 and CD59, in Daudi and Raji cells as well as in cells obtained from patients with B-cell malignancies (BCM). Antibody inducing direct antiproliferative and apoptotic effect, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) were tested separately. In Daudi and Raji cells, the CDC effect of rituximab significantly increased within 12 h following incubation with CMC-544. The levels of CD22 and CD55 were significantly reduced (P
- Subjects :
- musculoskeletal diseases
Cancer Research
Lymphoma, B-Cell
Sialic Acid Binding Ig-like Lectin 2
Antineoplastic Agents
macromolecular substances
Antibodies, Monoclonal, Humanized
chemistry.chemical_compound
immune system diseases
Cell Line, Tumor
hemic and lymphatic diseases
Calicheamicin
medicine
Humans
Cytotoxic T cell
Inotuzumab Ozogamicin
DNA Primers
CD20
Antibody-dependent cell-mediated cytotoxicity
Inotuzumab ozogamicin
Base Sequence
biology
Reverse Transcriptase Polymerase Chain Reaction
business.industry
Antibody-Dependent Cell Cytotoxicity
technology, industry, and agriculture
Antibodies, Monoclonal
Hematology
Flow Cytometry
Raji cell
Oncology
chemistry
Immunology
Monoclonal
biology.protein
Cancer research
Rituximab
business
medicine.drug
Subjects
Details
- ISSN :
- 14765551 and 08876924
- Volume :
- 23
- Database :
- OpenAIRE
- Journal :
- Leukemia
- Accession number :
- edsair.doi.dedup.....fd659e65554e7f52d32276ad4d8fb250